The estimated Net Worth of Pankaj Mohan is at least $1.09 Million dollars as of 27 October 2023. Dr Mohan owns over 34,375 units of Sonnet BioTherapeutics Inc stock worth over $48,532 and over the last 9 years he sold SONN stock worth over $253,923. In addition, he makes $792,166 as Founder and Chairman. CEO & Pres at Sonnet BioTherapeutics Inc.
Dr has made over 7 trades of the Sonnet BioTherapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 34,375 units of SONN stock worth $28,026 on 27 October 2023.
The largest trade he's ever made was buying 371,600 units of Sonnet BioTherapeutics Inc stock on 15 May 2023 worth over $81,752. On average, Dr trades about 47,946 units every 143 days since 2016. As of 27 October 2023 he still owns at least 59,526 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Dr Mohan stock trades at the bottom of the page.
Dr. Pankaj Mohan Ph.D. is the Founder, Chairman. CEO & Pres at Sonnet BioTherapeutics Inc.
As the Founder and Chairman. CEO & Pres of Sonnet BioTherapeutics Inc, the total compensation of Dr D at Sonnet BioTherapeutics Inc is $792,166. There are no executives at Sonnet BioTherapeutics Inc getting paid more.
Dr D is 56, he's been the Founder and Chairman. CEO & Pres of Sonnet BioTherapeutics Inc since . There are 4 older and 2 younger executives at Sonnet BioTherapeutics Inc. The oldest executive at Sonnet BioTherapeutics Holdings Inc is Dr. John K. Cini Ph.D., 68, who is the Chief Scientific Officer & Co-Founder.
Pankaj's mailing address filed with the SEC is 100 OVERLOOK CENTER,, SUITE 102, PRINCETON,, NJ, 08540.
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over $53,380 worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth $290,512 . The most active insiders traders include Pankaj Mohan, Donald J. Griffith, and Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of $21,474. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth $12,739.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: